225 related articles for article (PubMed ID: 36189258)
1. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Hong T; Su W; Pan Y; Tian C; Lei G
Front Immunol; 2022; 13():951459. PubMed ID: 36189258
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
3. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():861525. PubMed ID: 35355983
[TBL] [Abstract][Full Text] [Related]
4. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.
Gao B; Wang Y; Lu S
Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201
[TBL] [Abstract][Full Text] [Related]
5. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract][Full Text] [Related]
6. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
Chen L; Zhou Q; Liu J; Zhang W
Front Immunol; 2021; 12():759565. PubMed ID: 34777372
[TBL] [Abstract][Full Text] [Related]
7. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.
Xu W; Nie C; Lv H; Chen B; Wang J; Wang S; Zhao J; He Y; Chen X
Front Immunol; 2022; 13():1010554. PubMed ID: 36275697
[TBL] [Abstract][Full Text] [Related]
9. The integration of machine learning and multi-omics analysis provides a powerful approach to screen aging-related genes and predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Shen J; Gao H; Li B; Huang Y; Shi Y
Aging (Albany NY); 2023 Jul; 15(14):6848-6864. PubMed ID: 37517087
[TBL] [Abstract][Full Text] [Related]
10. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract][Full Text] [Related]
11. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
Xiao X; Mo H; Tu K
Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
[TBL] [Abstract][Full Text] [Related]
12. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.
Zhang G; Lv X; Yang Q; Liu H
BMC Cancer; 2022 Aug; 22(1):888. PubMed ID: 35964022
[TBL] [Abstract][Full Text] [Related]
13. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
14. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
Yuan J; Liu Z; Wu Z; Yang J; Yang J
Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
[TBL] [Abstract][Full Text] [Related]
15. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
16. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.
Ning Y; Fang S; Fang J; Lin K; Nie H; Xiong P; Qiu P; Zhao Q; Wang H; Wang F
Cancer Med; 2023 Aug; 12(16):17504-17521. PubMed ID: 37551111
[TBL] [Abstract][Full Text] [Related]
17. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma.
Qi L; Chen S; Liao Z; Fan M; Zhang J; Gao Y; Shen J; Sun Y; Wang Q
Aging (Albany NY); 2024 Feb; 16(5):4445-4468. PubMed ID: 38421251
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of Robust Hepatocellular Carcinoma Prognostic Subtypes Based on an Integrative Metabolite-Protein Interaction Network.
Chen D; Zhang Y; Wang W; Chen H; Ling T; Yang R; Wang Y; Duan C; Liu Y; Guo X; Fang L; Liu W; Liu X; Liu J; Otkur W; Qi H; Liu X; Xia T; Liu HX; Piao HL
Adv Sci (Weinh); 2021 Sep; 8(17):e2100311. PubMed ID: 34247449
[TBL] [Abstract][Full Text] [Related]
20. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
